TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. ('Orient EuroPharma'; TPEX: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marking the final step toward the commercial launch of Trogarzo in Taiwan.